免疫的药物 IMM-1-104 获得 FDA 快速通道状态，用于治疗晚期耐药性黑色素瘤。 Immuneering's drug IMM-1-104 gains FDA Fast Track status for treating advanced, resistant melanoma.

免疫公司获得FDA快速通道指标, 药物IMM-1-104治疗晚期黑色素瘤的患者, Immuneering Corp. received FDA Fast Track designation for its drug IMM-1-104 to treat advanced melanoma in patients who haven't responded to other treatments. 该药物是一种MEK抑制剂,在早期试验中表现出良好的耐受性,目前正在第2阶段对黑素瘤进行临床研究。 The drug, a MEK inhibitor, showed good tolerance in early trials and is currently in Phase 2a clinical studies for melanoma. 此前,它曾获得关于胰腺癌和孤儿药物地位的快车道指定。 It previously received Fast Track designation for pancreatic cancer and Orphan Drug status.